| Literature DB >> 25964840 |
Jung Hyun Park1, In-Chang Cho2, Yoo Seok Kim2, Soon Ki Kim2, Seung Ki Min2, So Shin Kye1.
Abstract
PURPOSE: There is no reported evidence for an anthropometric index that might link obesity to men's sexual health. We evaluated the ability of an anthropometric index and the symptom scores of five widely used questionnaires to detect men's health problems. We determined the predictive abilities of two obesity indexes and other clinical parameters for screening for lower urinary tract symptoms and sexual dysfunction in middle-aged men.Entities:
Keywords: Body mass index; Lower urinary tract symptoms; Metabolic syndrome X; Physiological sexual dysfuntion; Waist-hip ratio
Mesh:
Substances:
Year: 2015 PMID: 25964840 PMCID: PMC4426511 DOI: 10.4111/kju.2015.56.5.386
Source DB: PubMed Journal: Korean J Urol ISSN: 2005-6737
Patient characteristics (n=1,899)
| Variable | Value |
|---|---|
| Age (y) | 53.0 (48.0-56.0) |
| prostate-specific antigen (ng/mL) | 0.72 (0.48-1.12) |
| Testosterone (ng/mL) | 4.58 (3.75-5.61) |
| eGFR (mL/min/1.73 m2) | 95.72 (86.28-107.89) |
| Body mass index (kg/m2) | 24.8 (23.3-26.4) |
| Total prostate volume (cm3) | 24.0 (20.0-28.0) |
| Waist-to-hip ratio | 0.93 (0.91-0.94) |
| International Prostate Symptom Score | 10 (6-16) |
| CPSI | 7 (4-13) |
| ADAM | 34 (26-44) |
| IIEF-5 | 18 (13-22) |
| Premature ejaculation diagnostic tool | 7 (4-11) |
| Metabolic syndrome | 636 (33.5) |
| Hypertension history | 392 (20.7) |
| Diabetes history | 162 (8.5) |
| Dyslipidemia history | 57 (3.0) |
Values are presented as median (interquartile range) or number (%).
eGFR, estimated glomerular filtration rate; CPSI, the National Institutes of Health Chronic Prostatitis Symptom Index; ADAM, androgen deficiency in aging males questionnaire; IIEF-5, International Index of Erectile Function-5.
Differences in men's general health score according to various parameters
| Variable | Severity | PSA (ng/mL) | TT (ng/mL) | eGFR | TPV (cm3) | MetS | Obesity by BMI | Central obesity by WHR |
|---|---|---|---|---|---|---|---|---|
| IPSS | No or mild | 0.92±0.81 | 4.73±1.39 | 99.42±16.02 | 23.6±6.7 | 253 (34.7) | 355 (49.7) | 436 (59.7) |
| Moderate to severe | 1.00±1.06 | 4.75±1.40 | 98.44±16.12 | 24.7±7.0 | 383 (32.8) | 527 (46.6) | 715 (61.2) | |
| p-value | 0.096 | 0.717 | 0.193 | 0.001 | 0.396 | 0.197 | 0.562 | |
| CPSI | No or mild | 0.95±0.88 | 4.76±1.39 | 98.99±16.06 | 24.2±6.8 | 532 (34.7) | 717 (48.2) | 938 (61.2) |
| Moderate to severe | 1.04±1.29 | 4.69±1.44 | 98.10±16.18 | 24.6±7.3 | 104 (28.4) | 165 (46.2) | 213 (58.2) | |
| p-value | 0.136 | 0.372 | 0.346 | 0.332 | 0.023 | 0.517 | 0.312 | |
| ADAM | No or mild | 0.97±0.97 | 4.73±1.37 | 98.89±15.54 | 24.3±6.9 | 353 (32.6) | 508 (48.5) | 650 (60.0) |
| Moderate to severe | 0.96±0.98 | 4.75±1.43 | 98.72±16.79 | 24.3±6.8 | 283 (34.7) | 374 (46.9) | 501 (61.4) | |
| p-value | 0.866 | 0.723 | 0.814 | 0.890 | 0.351 | 0.510 | 0.569 | |
| IIEF-5 | No or mild | 0.96±0.90 | 4.75±1.39 | 98.58±15.22 | 24.3±6.9 | 500 (32.2) | 719 (47.4) | 912 (58.7) |
| Moderate to severe | 1.00±1.28 | 4.71±1.42 | 99.89±19.51 | 24.4±7.1 | 136 (39.4) | 163 (49.5) | 239 (69.3) | |
| p-value | 0.428 | 0.642 | 0.171 | 0.789 | 0.012 | 0.503 | <0.001 | |
| PEDT | No or mild | 0.99±1.03 | 4.74±1.37 | 98.59±15.92 | 24.2±7.1 | 379 (32.7) | 541 (47.9) | 696 (60.1) |
| Moderate to severe | 0.93±0.89 | 4.75±1.44 | 99.16±16.35 | 24.5±6.6 | 257 (34.7) | 341 (47.6) | 455 (61.5) | |
| p-value | 0.156 | 0.811 | 0.452 | 0.459 | 0.370 | 0.924 | 0.563 |
Values are presented as mean±standard deviation or number (%).
PSA, prostate-specific antigen; TT, total testosterone; eGFR, estimated glomerular filtration rate; TPV, total prostate volume; MetS, metabolic syndrome; BMI, body mass index; WHR, waist-to-hip ratio; IPSS, International Prostate Symptom Score; CPSI, the National Institutes of Health Chronic Prostatitis Symptom Index; ADAM, androgen deficiency in aging males questionnaire; IIEF-5, International Index of Erectile Function-5; PEDT, premature ejaculation diagnostic tool.
Logistic regression analyses predicting moderate to severe LUTS (IPSS≥8)
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| p-value | OR | 95% CI | p-value | OR | 95% CI | |
| Age | <0.001 | 1.041 | 1.020-1.062 | 0.001 | 1.034 | 1.014-1.056 |
| PSA | 0.101 | 1.092 | 0.983-1.213 | - | - | - |
| Testosterone | 0.717 | 1.012 | 0.947-1.082 | - | - | - |
| eGFR | 0.193 | 0.996 | 0.990-1.002 | - | - | - |
| TPV | 0.001 | 1.024 | 1.010-1.038 | 0.010 | 1.019 | 1.004-1.033 |
| MetS (non-MetSa vs. MetS) | 0.395 | 0.919 | 0.756-1.117 | - | - | - |
| BMI | 0.201 | 0.975 | 0.939-1.013 | - | - | - |
| WHR | 0.744 | 1.474 | 0.143-15.172 | - | - | - |
LUTS, lower urinary tract symptoms; IPSS, International Prostate Symptom Score; OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen; eGFR, estimated glomerular filtration rate; TPV, total prostate volume; MetS, metabolic syndrome; BMI, body mass index; WHR, waist-to-hip ratio.
a:Reference value.
Logistic regression analyses predicting moderate to severe CP-like symptoms (CPSI≥15)
| Variable | Univariate | ||
|---|---|---|---|
| p-value | OR | 95% CI | |
| Age | 0.680 | 1.005 | 0.981-1.030 |
| PSA | 0.143 | 1.081 | 0.974-1.199 |
| Testosterone | 0.372 | 0.963 | 0.887-1.046 |
| eGFR | 0.346 | 0.997 | 0.989-1.004 |
| TPV | 0.332 | 1.008 | 0.992-1.025 |
| MetS (non-MetSa vs. MetS) | 0.022 | 0.747 | 0.581-0.959 |
| BMI | 0.199 | 0.969 | 0.924-1.017 |
| WHR | 0.205 | 0.162 | 0.010-2.711 |
CP, chronic prostatitis; CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen; eGFR, estimated glomerular filtration rate; TPV, total prostate volume; MetS, metabolic syndrome; BMI, body mass index; WHR, waist-to-hip ratio.
a:Reference value.
Logistic regression analyses predicting moderate to severe aging male's symptoms (ADAM≥37)
| Variable | Univariate | ||
|---|---|---|---|
| p-value | OR | 95% CI | |
| Age | 0.018 | 1.024 | 1.004-1.045 |
| PSA | 0.866 | 0.992 | 0.904-1.089 |
| Testosterone | 0.722 | 1.012 | 0.948-1.080 |
| eGFR | 0.814 | 0.999 | 0.994-1.005 |
| TPV | 0.332 | 1.008 | 0.992-1.025 |
| MetS (non-MetSa vs MetS) | 0.340 | 1.098 | 0.906-1.331 |
| BMI | 0.448 | 1.015 | 0.997-1.054 |
| WHR | 0.381 | 2.801 | 0.279-28.095 |
ADAM, Androgen Deficiency in Aging Males questionnaire; OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen; eGFR, estimated glomerular filtration rate; TPV, total prostate volume; MetS, metabolic syndrome; BMI, body mass index; WHR, waist-to-hip ratio.
a:Reference value.
Logistic regression analyses predicting moderate to severe erectile dysfunction (IIEF-5≤11)
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| p-value | OR | 95% CI | p-value | OR | 95% CI | |
| Age | <0.001 | 1.125 | 1.093-1.159 | <0.001 | 1.121 | 1.087-1.156 |
| PSA | 0.430 | 1.045 | 0.936-1.167 | - | - | - |
| Testosterone | 0.642 | 0.980 | 0.902-1.066 | - | - | - |
| eGFR | 0.171 | 1.005 | 0.998-1.012 | - | - | - |
| TPV | 0.789 | 1.002 | 0.986-1.019 | - | - | - |
| MetS (non-MetSa vs MetS) | 0.010 | 1.372 | 1.078-1.745 | 0.036 | 1.323 | 1.018-1.720 |
| BMI | 0.506 | 1.017 | 0.968-1.067 | - | - | - |
| WHR | 0.016 | 47.683 | 2.080-1,093.027 | 0.814 | 1.479 | 0.056-38.857 |
IIEF-5, International Index of Erectile Function-5; OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen; eGFR, estimated glomerular filtration rate; TPV, total prostate volume; MetS, metabolic syndrome; BMI, body mass index; WHR, waist-to-hip ratio.
a:Reference value.